Vext Extends Engagement with Zuanic & Associates

Rhea-AI Summary

Vext Science (CSE: VEXT) (OTCQX: VEXTF), a U.S.-based cannabis operator with operations in Arizona and Ohio, has expanded its engagement with Zuanic & Associates through a Revised Services Agreement. Under the new agreement, Zuanic will provide advisory, research, and investor relations services to Vext for an initial twelve-month term starting October 1, 2024. The services will be provided for a monthly cash fee not exceeding US$7,000. Zuanic, an arm's length financial consulting and research advisory firm based in New Jersey, will deliver these services through various mediums and platforms.

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2024) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company"), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, today announced that it has entered into an agreement (the "Revised Services Agreement") with Zuanic & Associates ("Zuanic") to expand the services previously provided by Zuanic under its prior engagement.

Pursuant to Revised Services Agreement, Zuanic will provide advisory, research and investor relations services to the Company over an initial twelve month term, beginning on October 1, 2024, for a monthly cash fee not to exceed US$7,000, subject to further extension in accordance with the Revised Services Agreement. Such services may be delivered in a variety of different mediums through different platforms.

Zuanic is a financial consulting and research advisory firm with an address at Five Greentree Centre, 525 Route 73, N Suite 104, Marlton, New Jersey 08053 USA and can be contacted via e-mail at pablo.zuanic@zuanicgroup.com or via telephone at 646-503-1687. Zuanic is arm's length to the Company.

For more details, contact the IR team at investors@vextscience.com.

About Vext Science, Inc.

Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio. Vext's expertise spans from cultivation through to retail operations in its key markets. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio, as well as through Vext's partnerships in other states. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations, with the Company having operated profitably since 2016. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value.

Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.

For more details on the Vapen brand:

Vapen website: VapenBrands.com

Instagram: @vapen

Facebook: @vapenbrands

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to the Revised Services Agreement, including but not limited to the provision of investor relations activities thereunder and the extension thereof, and other statements regarding future developments and the business and operations of the Vext, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at www.sedarplus.ca.

Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Eric Offenberger
Chief Executive Officer
844-211-3725

For further information:
Jonathan Ross, Vext Investor Relations
jon.ross@loderockadvisors.com
416-244-9851

SOURCE: Vext Science, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232392

FAQ

What services will Zuanic & Associates provide to Vext Science (VEXTF) under the new agreement?

Under the Revised Services Agreement, Zuanic & Associates will provide advisory, research, and investor relations services to Vext Science through various mediums and platforms.

How much will Vext Science (VEXTF) pay Zuanic & Associates for their services?

Vext Science will pay Zuanic & Associates a monthly cash fee not exceeding US$7,000 for their services.

When does the new service agreement between Vext Science (VEXTF) and Zuanic & Associates begin?

The initial twelve-month term of the Revised Services Agreement begins on October 1, 2024.